Adsorptive depletion of elevated proinflammatory CD14CD16 DR monocytes in patients with inflammatory bowel disease
American Journal of Gastroenterology, ISSN: 0002-9270, Vol: 103, Issue: 5, Page: 1210-1216
2008
- 95Citations
- 41Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations95
- Citation Indexes95
- 95
- CrossRef79
- Captures41
- Readers41
- 41
- Mentions1
- News Mentions1
- News1
Most Recent News
Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast
STUDY INFORMATION OFFICIAL TITLE: An Investigator Initiated Study of Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast CURRENT STATUS: Recruiting STUDY
Article Description
BACKGROUND: In human blood, two monocyte populations exist, CD14 CD16 classical monocytes and CD14CD16 proinflammatory monocytes, which account for about 10% of total monocytes, but can expand to promote inflammatory conditions. CD14 CD16 monocytes produce large amounts of inflammatory cytokines including TNF-α and IL-1. Adacolumn adsorptive carriers adsorb from the blood in the column most of the monocytes/macrophages and granulocytes and this has been associated with clinical efficacy in patients with active inflammatory bowel disease (IBD). This study was to investigate the CD14 CD16 monocyte profile in patients with IBD and the impact of Adacolumn on this proinflammatory phenotype. METHODS: A total of 58 patients with ulcerative colitis (UC, N = 37) or Crohn's disease (CD, N = 21) together with 11 healthy controls were included in this study. Peripheral blood CD14CD16 monocytes were determined by three-color immunofluorescence and flow cytometry. RESULTS: The percentage of CD14 CD16 monocytes in patients with active CD was significantly (P = 0.0089) higher than the level in the control group, in patients with quiescent CD (P = 0.0419) or quiescent UC (P = 0.0063). Further, the percentage of CD14CD16 monocytes in patients with active UC who were on prednisolone (PSL) was less than the level in those not on PSL (P < 0.0001), thus PSL might have a suppressive effect on CD14 CD16 monocytes. Patients with active IBD were each given up to 10 Adacolumn granulocye/monocyte adsorption (GMA) sessions over an 8-wk period. The percentage of CD14CD16 monocytes decreased dramatically (P = 0.0077 in UC and P = 0.0117 in CD) compared with entry levels. CONCLUSIONS: A significant reduction in peripheral CD14CD16 monocytes by GMA should mitigate the inflammatory drive and contribute to the clinical efficacy of this procedure. Reduction of CD14 CD16 monocytes by corticosteroids was also seen. Hence, corticosteroids should enhance the efficacy of GMA. This is the first report on CD14CD16 monocytes being decreased by Adacolumn GMA in patients with IBD. © 2008 by Am. Coll. of Gastroenterology.
Bibliographic Details
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know